Profound Medical Corp.

Informe acción TSX:PRN

Capitalización de mercado: CA$271.0m

Profound Medical Dirección

Dirección controles de criterios 4/4

El CEO de Profound Medical's es Arun Menawat , nombrado en Aug 2016, tiene una permanencia de 7.67 años. compensación anual total es $889.95K, compuesta por 41.6% salario y 58.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.89% de las acciones de la empresa, por valor de CA$5.21M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 4.6 años, respectivamente.

Información clave

Arun Menawat

Chief Executive Officer (CEO)

US$889.9k

Compensación total

Porcentaje del salario del CEO41.6%
Permanencia del CEO7.8yrs
Participación del CEO1.9%
Permanencia media de la dirección2.1yrs
Promedio de permanencia en la Junta Directiva4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

May 03
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

Sep 15
Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Sep 07
Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Jan 07
Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Jul 02
We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

May 13
We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

May 07
Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

Mar 25
We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?

Mar 04
How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?

Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

Jan 27
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Arun Menawat en comparación con los beneficios de Profound Medical?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$890kUS$370k

-US$29m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$916kUS$344k

-US$29m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$4mUS$481k

-US$31m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$1m

-US$22m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$2mUS$531k

-US$15m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019n/an/a

-US$14m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$672kUS$509k

-US$15m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$264kUS$264k

-US$15m

Compensación vs. Mercado: La compensación total ($USD889.95K) de Arun está en línea con el promedio de empresas de tamaño similar en el mercado Canadian ($USD734.01K).

Compensación vs. Ingresos: La compensación de Arun ha sido consistente con los resultados de la empresa en el último año.

CEO

Arun Menawat (69 yo)

7.8yrs

Permanencia

US$889,948

Compensación

Dr. Arun Swarup Menawat, Ph D., MBA, served as the Chairman at Firefly Neuroscience, Inc. and is its Director. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the Chief Executive O...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Arun Menawat
Chairman of the Board & CEO7.8yrsUS$889.95k1.89%
$ 5.1m
Rashed Dewan
Chief Financial Officer3.1yrsUS$669.26k0.097%
$ 263.4k
Mathieu Burtnyk
Chief Operating Officerless than a yearUS$396.81k0.055%
$ 150.3k
Hartmut Warnken
Chief Commercial Officer of Outside US1.8yrsUS$226.17k0.0039%
$ 10.5k
Abbey Goodman
Chief Commercial Officer of US1.8yrsUS$555.98k0%
$ 0
Stephen Kilmer
Investor Relationsno datasin datossin datos
Jacques Cornet
Senior VP & Product Leader Sonalleve2.4yrssin datossin datos
Matthew Sobczyk
Assistant Corporate Controllerno datasin datossin datos
Levant Tinaz
Software Developerno datasin datossin datos

2.1yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PRN se considera experimentado (2 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Arun Menawat
Chairman of the Board & CEO9yrsUS$889.95k1.89%
$ 5.1m
Arthur L. Rosenthal
Independent Director6yrsUS$101.96k0.071%
$ 191.9k
Brian Ellacott
Independent Lead Director6yrsUS$102.91k0.28%
$ 754.4k
Cynthia Lavoie
Independent Director3.3yrsUS$97.91k0.025%
$ 66.6k
Mark Emberton
Member of Clinical Advisory Boardno datasin datossin datos
Murielle Lortie
Independent Director3.6yrsUS$100.41k0.013%
$ 34.9k
Eric Klein
Member of Clinical Advisory Boardno datasin datossin datos
Laurence Klotz
Member of Clinical Advisory Board1.7yrssin datossin datos
Scott Eggener
Member of Clinical Advisory Boardno datasin datossin datos
Adam Kibel
Member of Clinical Advisory Boardno datasin datossin datos
Aytekin Oto
Member of Clinical Advisory Boardno datasin datossin datos
Ian Thompson
Member of Clinical Advisory Boardno datasin datossin datos

4.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de PRN se considera experimentada (4.6 años de antigüedad promedio).